Interventional Management of Stroke (IMS) II Study

Phase 2 Completed 81 enrolled University of Cincinnati National Institute of Neurological Disorders and Stroke (NINDS) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the effects of delivering intra-arterial recombinant tissue plasminogen activator (rt-PA) and ultrasound to the site of the blood clot blocking blood flow to the brain of stroke patients.

Timeline

Start: 2003-01
Primary completion: 2006-05
Completion: 2007-05

Publications

Background IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007 Jul;38(7):2127-35. doi: 10.1161/STROKEAHA.107.483131. Epub 2007 May 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alteplase	Protein / enzyme biologic	0.6 mg/kg	Intravenous
Subject	Alteplase	Protein / enzyme biologic	22 mg	Intravenous

Interventional Management of Stroke (IMS) II Study

Summary

Timeline

Publications

Drugs

Indications